Tranexamic Acid Therapeutic Cheat Sheet
Tranexamic acid (TXA) is a synthetic lysine derivative that reversibly blocks the lysine-binding site on plasminogen, preventing conversion to plasmin. While originally developed as an antifibrinolytic agent to reduce bleeding, TXA has several downstream effects that make it useful in dermatology, particularly for pigmentary disorders, with emerging evidence in inflammatory disorders as well. TX …
Tranexamic acid (TXA) is a synthetic lysine derivative that reversibly blocks the lysine-binding site on plasminogen, preventing conversion to plasmin. While originally developed as an antifibrinolytic agent to reduce bleeding, TXA has several downstream effects that make it useful in dermatology, particularly for pigmentary disorders, with emerging evidence in inflammatory disorders as well. TX … 
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. … 
Cabtreo is the first FDA-approved fixed-dose triple-combination topical treatment for acne vulgaris, pairing a lincosamide antibiotic (clindamycin), a synthetic retinoid (adapalene), and a keratolytic oxidizing agent (benzoyl peroxide) into a single once-daily gel. This formulation targets several pillars of acne pathogenesis simultaneously: cutaneous C. acnes proliferation, abnormal keratinizatio … 
Antihistamines, particularly second-generation histamine H1-receptor antagonists, are widely used in dermatology due to their antihistaminic activity and favorable safety profile characterized by minimal sedation compared with first-generation agents. They primarily act as peripheral H1-receptor antagonists, reducing histamine-mediated effects such as vasodilation, increased vascular permeability, … 
Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, is a cornerstone in the evolving field of immuno-oncology. Originally developed for advanced cancers, nivolumab functions by blocking PD-1–mediated immune suppression, thereby enhancing T-cell–mediated antitumor responses. In dermatology, its relevance has grown not only because of its utility in melanoma treatment and cutaneo …